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Investigational Treatments: Coverage,
Controversy, and Consensus
Mary Ader*
INTRODUCrION
It is becoming commonplace. Most readers of this article
know someone, a friend or family member perhaps, who has
been diagnosed with a terminal disease, who has been told that
the only hope of survival is an innovative therapy still being con-
ducted in clinical trials, and whose insurance company will not
cover the treatment on the basis that it is still investigational1
and therefore excluded under the terms of the insurance policy.
It is hard to imagine a more distressing situation than having a
life-threatening disease with a poor prognosis, yet with a chance
of a cure but no chance of coverage. Since many of these inno-
vative treatments are prohibitively expensive-high-dose chem-
otherapy with autologous bone marrow transplant (HDC-
ABMT) or peripheral stem cell rescue, for example, might cost
up to $150,000 or more-many patients feel that they have no
recourse but to sue their insurer.
Over the past few years, scores of such lawsuits have been
filed, with varying and inconsistent results. Simultaneously, in
an effort to provide a more definitive resolution, many state leg-
islatures are debating or enacting legislation that mandates
third-party payment for certain investigational therapies. These
statutes vary widely in scope and effect.2 Therefore, the likeli-
* Ms. Ader is the General Counsel of Family Health Network, Inc. She served as
an Associate General Counsel to Blue Cross & Blue Shield Association in its Legal &
Corporate Division. Ms. Ader received her Bachelor of Arts in Law with Honors
from the University of Hull in England, and her Master of Laws from Northwestern
University School of Law.
1. The term "investigational," for purposes of this article, means that the proce-
dure is under investigation, and that the evidence on safety and effectiveness is still
inconclusive. Different insurers use different terms to describe this concept, including
"experimental" and "not medically accepted."
2. Some state statutes mandate coverage of specific procedures for specific diag-
noses. For example, Massachusetts, MASS. GEN. LAWS ANN. ch. 32A, § 17A (West
Supp. 1996), Minnesota, MINN. STAT. ANN. § 62A.309 (West 1996), and New Hamp-
shire, N.H. REV. STAT. ANN. § 415:18-c (Supp. 1995), mandate coverage of HDC-
ABMT for breast cancer. Some states, such as Virginia, VA. CODE ANN. § 38.2-
3418.1:1 (Michie 1994), mandate the offer of coverage. Other states, such as Florida,
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hood of securing access to innovative treatment is subject to so
many variables-benefit language, judicial interpretation, state
law-that a patient's prospects of securing such treatment are,
at best, unpredictable. This article outlines some of the legal and
medical controversies surrounding payment for investigational
treatments, and offers some thoughts on how these issues may
be resolved more constructively and systematically. Tradition-
ally, health plans have paid only for what works ("mainstream
medicine") and have excluded coverage of what is yet unproven
("medical research"). However, in light of this current contro-
versy, perhaps the time has come for health plans3 to reconsider
their position and begin to support the quest for scientific evi-
dence by contributing to clinical trials in certain appropriate cir-
cumstances. This article explores when appropriate
circumstances might exist, and highlights the benefits that would
flow from encouraging cooperation and developing consensus
among all the parties to this debate.
I. DEVELOPING A RATIONAL OBJECTIVE
The parties to the debate over investigational treatments have
many legitimate, and sometimes conflicting, perspectives. First,
health plan beneficiaries, faced with life-threatening diseases,
expect their health plans to cover anything that may save their
lives, including treatment that is still under investigation in re-
search programs. Second, health plans, by contrast, are reluc-
tant to pay for investigational treatments. Rather, they prefer to
purchase coverage of medically accepted care, to protect pa-
tients from unsafe and ineffective treatments, and to control
premium costs for all plan participants. Third, researchers and
providers of care, faced with dwindling research revenues from
other sources, are keen to acquire third-party payment to help
support their medical research. Fourth, courts and state legisla-
tures, perceiving human and societal needs amidst these con-
flicts, proceed to address these needs in ways that are often
inconsistent and at odds with medical science.
FLA. STAT. ANN. § 627.4236 (West Supp. 1996), have established an advisory panel to
consider the various interests and make recommendations on coverage. Yet other
states, for example, Rhode Island, R.I. GEN. LAWS § 27-18-36.2 (1989), require that all
experimental cancer therapies be covered when certain criteria are met.
3. Throughout this article, the term "health plans" is used instead of the individual
or group of individuals who maintain a particular position within the health plan. This
generic term is used because of the wide range of individuals who may hold the rele-
vant position in various insurance or managed care structures.
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The way to accommodate these different but perfectly valid
perspectives for the common good is to develop a rational ap-
proach to which all interested parties can subscribe. The parties
include research institutions, providers, payers, patients, and
lawmakers.
To convert the current controversy into consensus, the respec-
tive parties will need to adopt the following fundamental princi-
ples. First, in the interest of evidence-based medical decision
making, the parties must submit to the authority, indeed the
supremacy, of scientific data over conflicting legislative, judicial,
and journalistic pronouncements. Second, in the interest of
quality care, the parties will have to agree that the clinical bene-
fits of the treatment under consideration outweigh the harms.
Third, in the interest of fiscal propriety, the parties will need to
acknowledge that certain financial constraints attach to the set-
ting of premiums for the benefit contracts issued, and that the
terms of these contracts must not intentionally be contorted to
cover clearly unintended treatments. For example, a contract
covering Phase III clinical trials for diagnosis "X' and treatment
"Y" means exactly that: it should not be stretched to include
coverage of Phase II clinical trials for diagnosis "A" and treat-
ment "B" as well.4 Therefore, developing a rational objective
means developing a mutual one, grounded in the common as-
sumptions of scientific integrity, clinical integrity, and fiscal in-
tegrity. Before exploring some specific suggestions on how to
move the debate from controversy to consensus, it is helpful to
understand the current context in which benefit contracts are
administered.
II. UNDERSTANDING THE CONTEXT OF BENEFITS
ADMINISTRATION
A. The Need To Set Limits
In any rational health care system, there are limitations on
coverage and on affordability. Health plans are in the unenvi-
able position of having to define and enforce these limits in the
face of astonishing technological development, vigilante con-
sumerism, and unprecedented judicial intervention. In deter-
mining coverage, health plans are caught in a crossfire: they
4. For example, in Dodd v. Blue Cross & Blue Shield Ass'n, 835 F. Supp. 888, 890
(E.D. Va. 1993), the plaintiffs alleged, in essence, that coverage of certain clinical trials
obligated payment of all clinical trials. The court granted summary judgment to the
defendant. Id. at 892.
1996]
3
Ader: Investigational Treatments: Coverage, Controversy, and Consensus
Published by LAW eCommons, 1996
Annals of Health Law
must face an insatiable demand for new technology, assure
safety and efficacy on a scientific basis prior to diffusion, and
contain the costs of covered health care. In order to set reason-
able and enforceable limits on coverage as well as capture the
benefit of new technology, all parties to this debate must be will-
ing to increase their level of communication and cooperation.
Without this cooperative spirit, health plans will continue to de-
fine coverage limits through benefit contract exclusions and
through their reliance on technology assessments, as described
below.
B. Setting Limits Through Benefit Contract Exclusions
To assure uniformity, health plans set forth in their plan con-
tract that which is covered and that which is excluded. Two ex-
clusions are relevant to setting limits: one based upon medical
necessity and the other addressing investigational treatment.
The two exclusions, and the concepts they represent, are some-
times confused and sometimes used interchangeably. However,
they serve different, but equally valid, purposes.
Medical necessity exclusions are designed to address the con-
cept of efficiency. They speak to the appropriateness of care
and the corresponding level of care for a given diagnosis. For
example, the plan administrator may question whether a diagno-
sis requires six months of acute hospital care. A number of
medical necessity lawsuits are in fact length-of-stay disputes.
(Many of these cases involve mentally ill patients, which may
suggest that there is more uncertainty over the diagnosis and
treatment of mental illness than there is over the concept of
medical necessity; the problem may be defining mental illness,
rather than defining what constitutes a medical necessity.)
Although medical necessity exclusions have been challenged in
the courts, it is important that health plans are not intimidated
5. See, e.g., Salley v. E.I. DuPont & Co., 966 F.2d 1011 (5th Cir. 1992); Hughes v.
Blue Cross of N. Cal., 245 Cal. Rptr. 273 (Cal. Ct. App.), review granted, 755 P.2d 355
(Cal. 1988), cause transferred by 768 P.2d 32 (Cal.), aff'd, 263 Cal. Rptr. 850 (Cal. Ct.
App. 1989), cert. dismissed, 495 U.S. 944 (1990). A significant medical necessity case
that did not involve psychiatric treatment is Katskee v. Blue Cross/Blue Shield of
Neb., 515 N.W.2d 645 (Neb. 1994). The plaintiff had a genetic predisposition to can-
cer-breast-ovarian carcinoma syndrome. Id. at 647. The court found that the plain-
tiff's condition constituted an "illness" within the meaning of the contract, and, thus,
the recommended treatment-radical prophylactic surgery to remove the uterus, ova-
ries, and fallopian tubes-should not have been denied on medical necessity grounds.
Id. at 652.
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into abandoning the exclusion or relinquishing the concept of
efficiency that the exclusion represents.
Investigational exclusions, by contrast, are designed to ad-
dress the safety and efficacy of emerging technologies. A proper
analysis of these issues begins with a review of the status of a
particular investigation. The language of the exclusion should
contain objective criteria that correlate to the continuing investi-
gation of the technology under consideration. The criteria
should answer the following question: Given this patient and
this diagnosis, is there enough evidence to establish that this
treatment will work? If available, technology assessments, de-
scribed below, should determine the outcome of this inquiry.
In terms of coverage, many accounts do not want to pay for
new technologies that have not yet proven their value. Payers
(and their accounts) recognize, however, that even where tech-
nology assessments have not been available, certain therapies
have slipped into common use because their benefits out-
weighed their potential to cause harm. This may, on occasion,
result in a double standard-some therapies may have been rig-
orously assessed while others have not. It is clear that there ex-
ists the need for both continuing and comprehensive assessment
and for adequate financing of promising medical research.
C. Setting Limits Through Technology Assessment
The other method of defining coverage limits is the use of
technology assessments to determine what medical care is nec-
essary, safe, and effective. Payers and their accounts want value
for their money-they will pay for what works. Technology as-
sessment is one means to this end.
Approximately seventy organizations nationwide perform
technology assessments, including such groups as major insurers,
medical societies, the federal government, and various research
organizations. The key product is a document that summarizes
the current state of knowledge concerning the technology in
question, including divergent evidence, areas of controversy,
and gaps in the knowledge base. It describes safety, efficacy,
and appropriate use based on the available evidence. If there is
insufficient scientific evidence from which to draw conclusions
as to safety, efficacy, and improved health outcomes-such as
length of life, ability to function, and quality of life-then payers
and their accounts are likely to require the development of such
evidence before they will regularly pay for the technology.
19961
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In this way, technology assessment addresses not the cost of
emerging technologies, but, more significantly, value for money.
The vital role that technology assessment plays in determining
sound medical policy has generally been underrated and some-
times even ignored or flouted by courts and legislatures. The
goal is to educate the populace about this pivotal means of de-
livering quality health care. With this in mind, making the pro-
cess of technology assessment understandable to a wider
audience will require a greater effort.
III. THE CONSEQUENCES OF ASSESSMENTS AND EXCLUSIONS
A. The Impact on the Quality of Care
When third-party payment is not forthcoming by virtue of an
assessment or exclusion, what impact does this have on the tech-
nology and on the quality of care? First, payment decisions
based on technology assessments and/or benefit exclusions may
in fact delay the diffusion of technologies eventually found to be
medically appropriate. 6 Sometimes there are prolonged periods
of uncertainty for technologies eventually proven to be benefi-
cial, for example, cochlear implants for children. This occurs
even though payers are committed to paying quickly to please
their customers, and committed to improving quality. Second,
and conversely, the benefits of new technologies may ultimately
prove to be small or nonexistent. Here, the decision to pay may
promote ineffective or even harmful technologies, for example,
thalidomide therapy, bowel removal for epilepsy, the freezing of
gastric ulcers, and the Garren gastric bubble. Safety should be
the first order of the day.
B. The Explosion of Litigation and the Lessons Learned
Finding the right balance is not always straightforward and
can be controversial. Currently, a number of technologies seem
to fall into a "grey" area of payment confusion and litigation,
such as high-dose chemotherapy with autologous bone marrow
transplant (HDC-ABMT) for breast cancer, growth hormones
for short-statured children, home uterine monitoring to detect
early labor, Positron Emissions Test (PET) scans, and radial ker-
atotomy. It is regrettable that every technological advance
6. Given a choice of possible treatments, providers generally opt for the one that
the third-party payer reimburses. Therefore, until the newer technologies are proven
safe and effective, and hence reimbursable, providers are reluctant to prescribe them.
[Vol. 5
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seems to be accompanied by payment battles, which are often
played out in the courts and the media. Surely these are inap-
propriate forums for determining access to investigational treat-
ments given the nature of the scientific issues that such
treatments present. The volume of this litigation clearly evi-
dences the need to develop more collaborative, systematic ways
of addressing the payment of investigational treatments.
During the past few years, innumerable patients have sought
access to investigational treatments through the courts.7 Many
of these patients have been successful for a variety of reasons,
including the sympathy factor, inadequate and ambiguous con-
tract language, and alleged negligent medical review on behalf
of the benefit plan.8 As a result of this litigation compelling ac-
cess to investigational treatments, drafters of benefit plans have
tightened their exclusionary language and strengthened their
medical review processes.
Nevertheless, the litigation continues. The outcomes-both
legal and clinical-are still unpredictable, leaving unanswered
some fundamental questions: Should health plans always ex-
clude investigational treatment? If so, how should health plans
define "investigational"? How should health plans determine
whether a particular treatment meets the definition? To health
care payers, it seems that the answers to these questions have
been misunderstood by those outside the health care payment
business-patients, providers, the media, and the courts.
The cases are instructive on certain key points, sending a clear
message to health plans that if they wish to exclude investiga-
tional treatments, their investigational exclusions need to con-
tain, at a minimum, four elements: (i) sound criteria for making
the decision; (ii) a description of the decisionmaking process;
(iii) language that is not ambiguous; and (iv) language that is
7. See, e.g., Cole v. Blue Cross & Blue Shield of Mass., 738 F. Supp. 42 (D. Mass.
1990); Harris v. Blue Cross & Blue Shield of Tex., 729 F. Supp. 49 (N.D. Tex. 1990).
For an extensive compilation of these cases, see MARY ADER & NELL LEWIS, INVES-
TIGATIONAL EXCLUSIONS: A SUMMARY OF THE CASELAW (October 1995) (on file
with the Annals of Health Law).
8. Where the plaintiff is seeking treatment for a life-threatening disease and the
defendant is a deep-pocket defendant such as an insurance company, these facts tend
to influence the outcome of litigation, regardless of the contract language at issue. In
this "David v. Goliath" context, courts have often found the contract language ambig-
uous, see, e.g., Bailey v. Blue Cross/Blue Shield of Va., 866 F. Supp. 277, 282 (E.D. Va.
1994), or have concluded that the medical review process was deficient or inadequate
in some way, see, e.g., Bucci v. Blue Cross-Blue Shield of Conn., 764 F. Supp. 728, 733
(D. Conn. 1991). See also ADER & LEwis, supra note 7.
1996]
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sufficient to put the subscriber on notice of what is and is not
covered.9 This is easier said than done! Courts called upon to
review complex medical and methodological questions will con-
strue ambiguity in contract language against payers. Therefore,
what is meant by "investigational" needs to be precisely defined
in the contract and specifically related to enforceable criteria.
C. The Development of Criteria for Determining
Investigational Status
Health plans have adopted different approaches to developing
standards or criteria for determining investigational status.
Some are better than others, but all have fallen victim to judicial
disapproval at one time or another. The first approach is to ac-
cept the standard of "professional consensus," a concept capable
of various definitions but generally left undefined in the benefit
contract. This open-ended approach, however, runs the risk of
becoming the consensus of the relevant professionals, which in
turn may become the consensus of the treatment's proponents.10
From the payer's perspective, this is a slippery slope.
A second approach is to refer to and adopt the positions of
other respected entities, such as the Federal Office of Technol-
ogy Assessment, the National Institutes of Health, or the Amer-
ican Medical Association. This approach is also problematic:
the entity selected may not have a position on a particular tech-
nology; the entity's position may be unclear, dated, or in conflict
with the position of other entities; and the subscriber still may
not receive adequate notice of what is or is not covered.11
The third approach is to use scientific criteria, such as those
used in the technology assessment program of Blue Cross and
Blue Shield Association.1 2 This approach recognizes that there
9. See, e.g., Dozsa v. Crum & Forster Ins. Co., 716 F. Supp. 131 (D.N.J. 1989);
Waldrip v. Connecticut Nat'l Life Ins. Co., 566 So. 2d 434 (La. Ct. App.), cert. denied,
571 So. 2d 650 (La. 1990), aff'd as amended, 573 So. 2d 1172 (La. Ct. App. 1991). See
also ADER & LEWIS, supra note 7.
10. See, e.g., Dozsa, 716 F. Supp. 131.
11. See, e.g., Waldrip, 566 So. 2d 434. Cf. Boland v. King County Medical Blue
Shield, 798 F. Supp. 638 (W.D. Wash. 1992) (a plan sponsor's reliance on a classifica-
tion produced by an independent third party did not create fiduciary duties in that
third party).
12. The five Blue Cross and Blue Shield Association Technology Evaluation Cri-
teria are:
(1) The technology must have final approval from the appropriate govern-
ment regulatory bodies.
This criterion applies to drugs, biological products, devices and
diagnostics.
[Vol. 5
8
Annals of Health Law, Vol. 5 [1996], Iss. 1, Art. 5
http://lawecommons.luc.edu/annals/vol5/iss1/5
1996] Investigational Treatments 53
is a difference between the systematic generation of objective
data and authoritative opinion. The latter may prevail in law-
suits in the short run, but it must inevitably yield to the former
in the long run. 13
* A drug or biological product must have final approval from the
Food and Drug Administration.
* A device must have final approval from the Food and Drug Admin-
istration for those specific indications and methods of use that Blue
Cross and Blue Shield Association is evaluating.
* Any approval that is granted as an interim step in the FDA regula-
tory process is not sufficient.
(2) The scientific evidence must permit conclusions concerning the effect
of the technology on health outcomes.
" The evidence should consist of well-designed and well-conducted
investigations published in peer-reviewed journals. The quality of
the body of studies and the consistency of the results are considered
in evaluating the evidence.
* The evidence should demonstrate that the technology can measure
or alter the physiological changes related to a disease, injury, illness
or condition. In addition, there should be evidence or a convincing
argument based on established medical facts that such measure-
ment or alteration affects the health outcomes.
" Opinions and evaluations by national medical associations, consen-
sus or other technology evaluation bodies are evaluated according
to the quality of the supporting evidence and rationale.
(3) The technology must improve the net health outcome.
* The technology's beneficial effects on health outcomes should out-
weigh any harmful effects on health outcomes.
(4) The technology must be as beneficial as any established alternatives.
* The technology should improve the net health outcome as much as
or more than established alternatives.
(5) The improvement must be attainable outside the investigational
settings.
When used under the usual conditions of medical practice, the technology should be
reasonably expected to satisfy criteria 3 and 4.
13. Some courts have decried the health plans' failure to specify the quantum of
evidence required and have called for specific thresholds of statistical success in terms
of cure or survival rates. See, e.g., Bucci v. Blue Cross-Blue Shield of Conn., 764 F.
Supp. 728 (D. Conn. 1991); Reiff v. Blue Cross & Blue Shield of Okla., No. 90-C-
1030-E (N.D. Okla. Feb. 11, 1991) (on file with the Annals of Health Law); Pirozzi v.
Blue Cross-Blue Shield of Va., 741 F. Supp. 586 (E.D. Va. 1990). With all due respect
to these courts, such a standard-for all diseases, all technologies, and all times-
simply could not be met; it would be utterly impracticable even to attempt to embrace
this standard in a single health benefit contract. Although these particular courts con-
demned the lack of standards for determining statistical success, at least one other
court, looking at the numbers, took a different view. Evans v. HMO Colo., Inc., No.
91CV3797 (Colo. Dist. Ct., Denver County June 14, 1991) (on file with the Annals of
Health Law). Here, the plaintiff sought benefits for HDC-ABMT for the treatment of
cervical cancer. The court found significant that the procedure had been performed
on only six patients at one research facility. It said: "[T]he University of Nebraska is
the only one that's been trying to find out if this is going to work on this kind of solid
cancerous form .... [N]obody knows yet. Everybody agrees that six is too few to
make a judgment on." Id. at 11.
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For health plans that want to cover only those treatments
proven to work, the scientific criteria approach, geared to the
systematic generation of objective data, appears to be the supe-
rior one. Such plans would specifically exclude treatments per-
formed in Phase I, II, or III clinical trials14 under protocols that
seek to determine safety, efficacy, and toxicity, and seek to com-
pare the investigational treatment with conventional alterna-
tives. These plans would also exclude treatments that call for
institutional review board approval and consent to investiga-
tional treatment.1 5
Regardless of a health plan's approach and objective, its con-
tract language will always be subject to legal challenge on the
grounds of ambiguity. Moreover, its medical review process will
be scrutinized for timeliness, comprehensiveness, and currency.
The burden of vigilance here, the courts say, falls on the health
plan.1 6 Another problem is the practice of lawyers who focus on
how to interpret benefit language, rather than on how to benefit
a patient or advance medical science. As a result of this "loop-
hole lawyering," clinical issues of safety and efficacy are lost.
IV. A RATIONAL ALTERNATIVE: ACCESS TO CLINICAL
TRIALS
Parties to litigation over investigational exclusions often find
themselves literally, as well as metaphorically, locked in mortal
combat in the courts. When potentially life-saving treatment is
at stake, trial courts are likely to rule in favor of the plaintiff/
patient. Defendants rarely appeal.' 7 Health plans have re-
sponded to this in a variety of ways: they have strengthened the
general investigational exclusion; they have developed proce-
14. Phase I clinical trials are designed to determine the reactions of the experi-
mental drug or procedure in humans, including side effects, effectiveness, and toxicity.
Phase II clinical trials are conducted to evaluate the effectiveness in humans of the
experimental drug or procedure on a particular condition or disease, with the goal of
gathering data on the effect/benefit that the drug provides. The goal of Phase III
clinical trials is to gather large amounts of data on the effectiveness and safety of an
experimental drug or procedure; this is usually accomplished by randomly providing
either experimental or conventional treatment to human subjects and comparing their
outcomes.
15. Institutional review board approval is required for all research that involves
the use of human subjects. See 45 C.F.R. 46.109, 46.101 (1996).
16. Contract language does not always contemplate new medical developments.
See, e.g., Bailey v. Blue Cross/Blue Shield of Va., 866 F. Supp. 277 (E.D. Va. 1994);
Calhoun v. Complete Health, Inc., 860 F. Supp. 1494 (S.D. Ala. 1994); McLaughlin v.
Williams, 801 F. Supp. 633 (S.D. Fla. 1992).
17. See generally ADER & LEWIS, supra note 7.
[Vol. 5
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dure-specific exclusions for certain treatments; they have been
more selective in those cases they choose to take to trial; and
they have offered riders for investigational treatments. All of
these responses have minimized, but not eliminated, the ele-
ment of uncertainty inherent in benefit language interpretation.
What these responses fail to do is answer the fundamental
question raised earlier: Should health plans be in the business
of excluding all investigational treatment in the first place? Is
this a defensible position? Expressed differently, is there a legit-
imate role for health plans to cover certain kinds of investiga-
tional treatment? If so, what might this role be? How should
benefit language be drafted? Can health plans develop a
"clinical trials benefit" provision?
With these questions in mind, it might be prudent for health
plans to begin to think about two categories of investigational
treatment, and to distinguish "bizarre" therapies from legitimate
medical research. The case law shows that the investigational
exclusion is an effective and appropriate barrier to paying for
"zany" treatment, such as coffee enemas and tomato therapies.' 8
However, for potentially life-saving treatments, the case law
suggests a trend that may render standard medical coverage lan-
guage insufficient to protect against claims for investigational
treatments. This trend is most notable when the plaintiff/patient
is diagnosed with a terminal illness and, but for the investiga-
tional therapy, life expectancy is limited; the investigational
therapy provides the only possibility to preserve life; the treat-
ment is prescribed by legitimate providers and performed in
leading institutions; and conventional therapy has failed.19 Even
the finest of investigational exclusions and decisionmaking
processes will face an uphill battle in court in life-threatening
cases if the plan is characterized as asking the court for a death
sentence for the subscriber. For these kinds of cases, health
plans may wish to consider developing humane, worthwhile al-
ternatives to claim denials. The funding of clinical trials would
be a logical place to begin.
18. Requests for payment for these kinds of therapies are often denied by the
plan's medical director, without recourse to the courts. For treatments involving apri-
cot pits and vitamin therapy, see Free v. Travellers Ins. Co., 551 F. Supp. 554 (D. Md.
1982) (laetrile treatments and vitamin regimens), and Henne v. Mutual of Omaha,
No. 81-1359 (D.D.C. Jan. 10, 1983) (on file with the Annals of Health Law).
19. See, e.g., Pirozzi v. Blue Cross-Blue Shield of Va., 741 F. Supp. 586 (E.D. Va.
1990) (Stage IV breast cancer).
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The adverse publicity and continuing litigation undermine the
efforts of many health plans, especially those that are not-for-
profit. In addition, these negative forces frustrate all health
plans that have in good faith set their premiums for their prod-
ucts based on the actuarial principles applied to the benefits in
their written contracts. Moreover, despite misguided attempts
by plaintiffs and the press to depict health plans as latter-day
Scrooges, the reality is that health plans routinely pay enormous
sums for appropriate noninvestigational treatment. For exam-
ple, HDC-ABMT is routinely covered for those diagnoses for
which it has been proven effective-at least six forms of cancer.
Accordingly, the conflict in the courts over contract interpre-
tation is but a symptom of a different and more fundamental
problem. The real issue to be addressed is not the enforceability
of the investigational exclusion, nor its wordsmithing, but rather
how to finance medical research. In earlier days, cancer and
heart disease were first in line for relatively abundant research
funds, and payers generally did not object to covering the pa-
tient care costs of this research. Today, however, the issues are
more complex: government resources are subject to budget con-
straints; new diseases have unprecedented political clout; bur-
geoning techno-med (or high-technology medicine) consumes
an increasing proportion of the health care dollar; and hospitals
and physicians look to medical research programs to solve pa-
tient census problems and contribute to the bottom line. Health
plans are now being tapped to fill the void and, as a result, fre-
quently balk, particularly if the research is in the early stages.
If the cost of medical research is to be shifted to health plans,
then two results would follow. First, health care premiums
might increase, at least in the short run. Health plans would be
covering additional care that would not necessarily be substitu-
tional in nature. Second, health plans would begin to consider
developing constructive payment mechanisms for investigational
procedures, and would then steer resources into research studies
in a timely manner. For example, they might rewrite their bene-
fit contracts to cover certain forms of investigational treatment
when provided in well-conceived clinical trials under specified
terms and conditions. Health plans would then be able to pool
the resulting data and learn something for the money they ex-
pended. This approach would stimulate valuable research and
yield useful information for the care of future patients. It would
represent a new era of collaboration and cooperation between
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health care payers and health care providers. Above all, this
way of promoting clinical trials would move the debate of
whether a particular treatment works from the legal to the med-
ical arena, where it belongs.
A logical way to begin this process would be for health plans
to engage in selective contracting with specified institutions for
promising treatments. For example, they might choose to pay
for all health care provided in Phase III trials, representing a
stage in the research that shows "substantial promise." This op-
tion could permit coverage only when the procedure was per-
formed at specified institutions or institutions that met specified
criteria-an "exclusive provider organization."
Variations on this "exclusive provider organization" theme,
and suggested contractual components of it, might include: (i)
contributing to controlled clinical trials, (ii) under research pro-
tocols (national if possible, to elicit comparable data), (iii)
within a designated time frame, (iv) with data analysis, (v) al-
lowing for cost sharing, and (vi) risk sharing. Each of these six
components is designed to reinforce the research and investiga-
tional nature of the procedure at issue. Cost sharing and risk
sharing might take a variety of forms: two way, between the
health plan and the health care provider, or even three way,
among the plan, the provider, and the patient/subscriber.
One example of such an approach is the Blue Cross and Blue
Shield System's Demonstration Project for HDC-ABMT treat-
ment of breast cancer, currently sponsored by Blue Cross and
Blue Shield Association (BCBSA) in conjunction with the Na-
tional Cancer Institute (NCI). The Blue Cross and Blue Shield
Plans expect to contribute approximately $40 million to this ran-
domized controlled clinical trial over the next several years. The
demonstration project supports a series of four national Phase
III trials. The NCI trials are intended for the eventual enroll-
ment of 1500 women and are currently being conducted at
eighty-six medical research institutions. The BCBSA has con-
tracts with forty-two of these institutions. Clinical trial coopera-
tive groups-voluntary associations of cancer research
institutions that conduct clinical trials executed uniformly
among member institutions-designed and approved the re-
search protocols governing each of the NCI trials. The NCI ap-
proved the research protocols. In addition, the trials are
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randomized20 so that the outcomes of the treatments can be sci-
entifically compared. This demonstration project should be
completed in 1998.
Another example of this kind of contracting is the BCBSA
multiple myeloma trial program. This program, modeled after
the breast cancer demonstration project, includes unique con-
tracts with a network of qualified institutions, access to trials
that are approved by a national research organization, a fixed
contribution rate negotiated with each institution, and a central-
ized patient management and tracking system.
A third example is BCBSA's response to the September 1994
federal government mandate that all carriers in the Federal Em-
ployee Health Benefits Program cover HDC-ABMT or periph-
eral stem cell rescue for three diagnoses: breast cancer, multiple
myeloma, and epithelial ovarian cancer. The BCBSA devel-
oped a "Clinical Trials Benefit," which covers these services
along with allogeneic bone marrow transplants for multiple my-
eloma when performed in a clinical trial.
Clinical trials are the only way to both resolve the relative
efficacy of new technologies and ensure that the patient is being
treated as safely as possible by the most competent physicians.
If there is a point at which medicine, economics, common law,
and common sense intersect, then the funding of clinical trials is
that point. There are periods of scientific uncertainty. These is-
sues can only be resolved scientifically, if at all. Orders or man-
dates of payment from courts, states, and accounts are not
responsive to this dilemma.
One final issue remains: How should we select clinical trials
that are worth financing and incorporating into the health care
benefit? Not all clinical trials are of the same value. Two princi-
ples should guide the selection. First, the trials selected should
be those that undergo the most rigorous protocol review process
and receive thorough study oversight. For HDC-ABMT treat-
ment of breast cancer, for example, the most strenuous level of
protocol review and oversight is received by NCI-sponsored
therapeutic clinical trials conducted by the Clinical Trials Coop-
erative Groups. Trials approved by other NCI programs or
other research entities recognized by the NCI for Cancer Center
support grants could be ranked second in importance for health
plan consideration. Trials approved only by a hospital institu-
20. Randomized trials are ethical only where the researchers do not know
whether the experimental therapy, the standard therapy, or either is superior.
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tional review board and funded by the institution or pharmaceu-
tical companies or other local sponsors should be ranked lowest
in importance for health plan consideration.
The second guiding principle is that patients should always be
treated in the highest phase of a trial for which they are eligible,
since this is the phase most likely to yield a positive health out-
come. Within the hierarchy of trial phases, Phase III mul-
ticenter controlled trials that compare investigational agents
with standard therapy should receive the highest priority for
health plans. Phase II trials, which determine antitumor activity
of agents generally in single-site trials, should be ranked second
in importance to Phase III trials for health plan support. Phase I
trials, which attempt to establish therapeutic effect and safe dos-
age, should generally be supported by the research sponsor and
not by payers.
CONCLUSION
Some may argue that to embrace this approach in a benefit
contract would cause health care insurance premiums to sky-
rocket. While premiums may well increase in the short term,
health plans will realize savings in the long run. Research re-
sults will reveal ineffective procedures and open avenues to ef-
fective patient treatments. As a result, health plans will no
longer pay for ineffective treatments and patient care will be
more efficacious. It is thus more productive for health plans to
steer their members into well-conceived clinical trials than to re-
main at the mercy of judicial or legislative mandates. For the
present, this seems the best hope for converting coverage con-
troversy into coverage consensus. In the future, it may yet come
to pass that a health plan's "clinical trials benefit" provision will
be the touchstone of quality for the entire health benefit
contract.
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Additional Resources
The following resources are quite helpful in understanding
and exploring the issue of paying for investigational treatment.
John H. Ferguson et al., Court-Ordered Reimbursement for Un-
proven Medical Technology: Circumventing Technology Assess-
ment, 269 JAMA 2116 (1993).
Mark A. Hall & Gerard F. Anderson, Health Insurers' Assess-
ment of Medical Necessity, 140 U. PA. L. REV. 1637 (1992).
Angela R. Holder, Funding Innovative Medical Treatment, 57
ALB. L. REV. 795 (1994).
David C. Hsia, Benefits Determination Under Health Care Re-
form, 15 J. LEGAL MED. 533 (1994).
Barbara A. Fisfis, Comment, Who Should Rightfully Decide
Whether a Medical Treatment Necessarily Incurred Should Be
Excluded From Coverage Under a Health Insurance Policy Pro-
vision Which Excludes From Coverage "Experimental" Medical
Treatments?, 31 DUQ. L. REV. 777 (1993).
Richard S. Saver, Note, Reimbursing New Technologies: Why
Are the Courts Judging Experimental Medicine?, 44 STAN. L.
REV. 1095 (1992).
Denise S. Wolf, Comment, Who Should Pay for "Experimental"
Treatments? Breast Cancer Patients v. Their Insurers, 44 AM. U.
L. REV. 2029 (1995).
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